



pharma& to Highlight Subsequent Therapy Data by HRD Status for Rubraca® (rucaparib) in Patients with Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2026 Annual Global Meeting

Intended for the healthcare media

Vienna, Austria, September 17, 2026 – pharmaand GmbH (pharma&), a global company dedicated to preserving the availability and fostering the further development of essential medicines to leave no patient behind, today announced that subsequent therapy data by homologous recombination deficiency (HRD) status for Rubraca® (rucaparib) in patients with advanced ovarian cancer will be presented in a Poster Round with the Professors session during the **International Gynecologic Cancer Society (IGCS) 2026 Annual Global Meeting**, October 1-3 in Montreal, Quebec.

Title: Patients with Newly Diagnosed Advanced Ovarian Cancer in ATHENA-MONO/GOG-3020/ENGOT-OV45: Subsequent Anti-Cancer Therapy by HRD Status

Presenter and Lead Author: Prof. Diane Provencher, MD, FRCSC, FACOG, University of Montreal, Montreal, Quebec

Session Time and Date: 10:30 a.m. ET, Saturday, Oct. 3

Location: Station 01, Exhibition Hall, Palais des Congrès de Montréal

This presentation will analyze subsequent therapy data by HRD status and build on the intent-to-treat data previously presented at the European Society for Medical Oncology Gynaecological Cancers (ESMO Gynae) Congress 2026 in Copenhagen, Denmark.

About the ATHENA Clinical Trial

ATHENA (GOG 3020/ENGOT-ov45) ([NCT03522246](#)) is an international, randomized, double-blind, phase III trial consisting of two separate and fully independently powered study comparisons evaluating rucaparib monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment for patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. ATHENA enrolled approximately 1000 patients across 24 countries, all women with newly diagnosed ovarian cancer who responded to their first-line chemotherapy. The trial completed accrual in 2020 and was conducted in association with the GOG Foundation, Inc. (GOG-F) in the U.S. and the European Network of Gynaecological Oncological Trial groups (ENGOT) in Europe. GOG-F and ENGOT are the two largest cooperative groups in the U.S. and Europe dedicated to the treatment of gynecological cancers.

ATHENA-MONO is evaluating the benefit of rucaparib monotherapy versus placebo in 538 women with advanced high-grade ovarian cancer. The primary efficacy analysis evaluated two prospectively defined molecular sub-groups in a step-down manner: 1) HRD-positive (inclusive of

BRCA mutant) tumors, and 2) the intent-to-treat population, or all patients treated in ATHENA-MONO.

About pharma& (pharmaand.com)

pharmaand GmbH (pharma&), a privately owned global company, aspires to breathe new life into proven medicines. The Company is dedicated to preserving the availability and fostering the further development of essential medicines worldwide to leave no patient behind. Since its inception, pharma& has acquired and integrated 10+ medicines, expanding its portfolio across a wide range of therapy areas, with an increasing focus on hematology and oncology treatments. The Company's unique synthesis of subsidiaries, joint ventures, and partners enables pharma& to provide its portfolio of medicines to eligible patients worldwide by spanning the continuum of research and development, in-house product and active pharmaceutical ingredients (API) manufacturing, distribution via its global partner network, healthcare provider engagement, patient safety services, and patient access services through U.S. Market Access.

#

pharma& Media Contact:

media@pharmaand.com